Disease characteristics and the impact of MDT on cancer-specific survival (CSS) was assessed using Cox proportional hazard models. CSS was measured from time of BCR following RPþPORT. A propensity-score matched pair analysis between SOC and MDT patients was performed based on known prognostic factors at initial diagnosis (PSA prior to RP, year of RP, RP Gleason Grade, age, pN-status and pT stage).
INTRODUCTION AND OBJECTIVES: Up front tailor-made wide excision surgery is sometimes offered to men as part of combined modality treatment with adjuvant radiotherapy þ/androgen deprivation therapy (ADT) for high risk and non-metastatic prostate cancer. Particularly young men want to avoid long periods of ADT which is required for primary radiotherapy treatment. Upfront surgery is therefore seen as a reasonable alternative to achieve cure without ADT. We prospectively assessed short term PSA recurrence rates, the need for adjuvant radiotherapy and ADT.
METHODS: 278 patients with high risk PCa (47.5% were locally advanced), underwent laparoscopic or robotic radical prostatectomy with pelvic lymphadenectomy from July 2007 to July 2016 at three inner London tertiary referral centres. D 0 Amico criteria (cT2c, PSA>20, Gleason grade 8-10) were used to define high risk. Supersensitive PSA measurements were used. PSA recurrence was defined as two tests results above 0.02. Kaplan-Meier survival estimates were generated. A small number of patients were offered radiotherapy þ/-ADT for undetectable PSA nadir based on the presence of pathological risk factors. Some patients were randomised to the RADICALS study(CRUK/07/ 008). Uni and multivariate analysis was performed on all available variables. Kaplan-Meier estimates were calculated. Cox multivariate regression analysis was computed to identify pre-and post-operative factors associated with PSA recurrence.
RESULTS: Median follow up was 34 months (range 0.9-98 months). Of all patients 55.4% did not have PSA recurrence, 38.1% required radiotherapy and 25.2% ADT. Positive margins (p¼0.014)and tumour volume (p¼0.041) were independently predictive of PSA recurrence. Tumour volume >4cm3 may be predictive of almost certain biochemical recurrence with supersensitive PSA. 5 year free recurrence survival was 51% globally and 50.3% and 18.4% for tumour volume <4cm3 and >4cm3 respectively. CONCLUSIONS: Young men may have a high chance to avoid ADT (75% in three years) if treated with surgery alone or in combination with radiotherapy. Tumour volume in addition to margin status is a strong predictor of biochemical recurrence in high risk prostate cancer. Since tumour volume can now be obtained pre-operatively with later generation CAD (computer-aided design) software it could be a meaningful pre-operative risk stratification tool for treatment selection and new study designs. METHODS: Data of patients were collected in prospectively maintained database after IRB approval. Inclusion criteria of the study were: 1) high-risk localized (PSA level 20 ng/ml or clinical stage T2c or Gleason score 8) or locally advanced (clinical stage T3 or Nþ, any PSA level, any Gleason score) prostate cancer after RP and PLND 2) patients suitable to receive CHT and RT after surgery. Exclusion criteria were: 1) uncontrolled chronic disease; severe infection; peripheral neuropathy or prior malignancy within the last 5 years before study entry; 2) prior CHT, pelvic RT or local treatments for prostate cancer. Adjuvant IMRT with concurrent Docetaxel and long-term ADT were stared after 3-6 months form surgery. IMRT was performed in 4 to 6 field technique with 15-to 18-MV. Docetaxel was administered in a standard 1-hour intravenous weekly dose (30 mg if body surface area <1.8 m2 and 40 mg if body surface area 1.8 m2) for 6-7 weeks. ADT was maintained for 2 years. Acute and late toxicity were evaluated with the Common Terminology Criteria for Adverse Events version 3.0. Biochemical and clinical recurrence-free survival were explored with the Kaplan-Meier method.
Source of Funding: None
RESULTS: Overall 42 patients were included in the study. Acute Genito-Urinary (GU) toxicity was observed with grade I, II and III in 4 (9.5%), 2 (4.8%), and 1 (2.3%) patients, respectively. Acute Gastro-Intestinal (GI) toxicity was found found with grade I and II in 12 (29.3%) and 3 (7.2%), respectively. In those patients with acute toxicity, concomitant GU and GI toxicity occurred in 3 (7.2%) cases. No acute grade IV toxicity was detected. A residual GU grade I toxicity was present only in 1 patient. Allergy due to CHT has been evaluated in 3/42 (7.1%) patients. Continence (defined as absence of e718 THE JOURNAL OF UROLOGY â Vol. 197, No. 4S, Supplement, Sunday, May 14, 2017 
